Open Access

Imipramine alters the sterol profile in Leishmania amazonensis and increases its sensitivity to miconazole

  • Valter Viana Andrade-Neto1,
  • Thaís Martins Pereira1,
  • Marilene do Canto-Cavalheiro1 and
  • Eduardo Caio Torres-Santos1Email author
Parasites & Vectors20169:183

https://doi.org/10.1186/s13071-016-1467-8

Received: 21 February 2016

Accepted: 21 March 2016

Published: 31 March 2016

Abstract

Background

Imipramine, a tricyclic antidepressant widely used clinically, has other pharmacological effects, such as antileishmanial activity. Tricyclic antidepressants interact with lipid bilayers, and some studies have shown that imipramine inhibits methyltransferases. Leishmania spp. produces compounds with an ergostane skeleton instead of a cholesterol skeleton, and the inhibition of enzymes of the sterol biosynthesis pathway is an interesting therapeutic target. Among these enzymes, C-24 methyltransferase has been suggested to play an essential role, as its inhibition kills the parasites. In this context, we investigated whether imipramine alters the biosynthesis of sterols in L. amazonensis and evaluated the efficacy of imipramine alone and in combination with miconazole, a classical inhibitor of another step in this pathway.

Methods

To analyze the interference of imipramine with sterol metabolism, promastigotes of L. amazonensis were cultured with medium alone, 15 or 30 μM imipramine or 4 μM miconazole, and their lipids were extracted with methanol/chloroform/water (1:0.5:0.4 v/v) and analyzed by GC/MS. To assess the antileishmanial activity of the treatments, promastigotes of L. amazonensis were incubated with various concentrations of imipramine up to 100 μM and up to 24 μM miconazole. Promastigotes were also treated with the combination of imipramine and miconazole at concentrations up to 12.5 μM of imipramine and 24 μM of miconazole. Parasite growth was evaluated by the MTT assay. The fractional inhibitory concentration index (FICI) was calculated to determine whether there were synergistic effects. Peritoneal macrophages with and without L. amazonensis infection were treated with miconazole (0 – 16 μM) or imipramine (0 to 50 μM) for 72 hours. For assays of the combined treatment in amastigotes, the concentration of imipramine was fixed at 12.5 μM and various concentrations of miconazole were used up to 16 μM. The infection rate was determined by counting the infected macrophages under a light microscope.

Findings

Promastigotes treated with imipramine accumulated cholesta-5,7,22-trien-3β-ol and cholesta-7-24-dien- 3β-ol, sterols that normally increase after treatment with classical inhibitors of C-24 methyltransferase. The IC50 of miconazole in promastigotes decreased when it was used in combination with imipramine, resulting in an additive effect, with a FICI value of 0.83. Imipramine also showed activity against intracellular amastigotes and enhanced the activity of miconazole, without apparent toxicity to the host cells.

Conclusions

Imipramine was confirmed to have antileishmanial activity in both forms of the parasite, affecting the sterol biosynthesis of the organisms. Using imipramine in combination with azoles may be advantageous for the treatment of leishmaniasis.

Keywords

Leishmania Imipramine Sterols

Background

Leishmaniasis is a disease caused by parasites of the genus Leishmania, unicellular eukaryotes belonging to class Kinetoplastea and family Trypanosomatidae. Leishmania spp. are transmitted by more than 20 species of sandflies of the genera Phlebotomus and Lutzomyia [1]. Leishmaniasis is a non-contagious infectious disease that can affect the skin and mucous membranes (cutaneous leishmaniasis) or internal organs (visceral leishmaniasis) [2, 3]. Endemic transmission of leishmaniasis is known to occur in 98 countries on five continents. It has been estimated that there were more than 58,000 cases of visceral leishmaniasis and 220,000 cases of cutaneous leishmaniasis [4].

Since the 1940s, the main treatment for leishmaniasis has included antimony derivatives that are commercially available in two formulations, N - methylglucamine antimoniate (meglumine antimoniate, Glucantime®) and sodium stibogluconate (Pentostam®) [5]. These drugs have many toxic effects, including cardiac, hepatic, pancreatic and renal toxicity, and should be used with caution and with clinical and laboratory monitoring in patients with heart or liver disease [6]. The efficiency of antimony may vary, and treatment protocols are determined depending on the region. Many cases of resistance have been reported, making treatment difficult [7]. Miltefosine, the only oral treatment, has been prescribed in India for visceral leishmaniasis for more than a decade and was recently approved by the FDA for all forms of this disease, but some concerns about resistance and teratogenicity have been raised [8, 9]. Other drugs, such as pentamidine and amphotericin B, may be used if resistance to the first-line treatment occurs, although these have major toxicity [5]. Furthermore, no vaccine for human use has been developed to date, although some studies have been carried out, such as a study of the protective role of serine proteases in the parasite [10]. Thus, there is a need to search for new strategies to control leishmaniasis.

Imipramine, a tricyclic antidepressant widely used in the clinical setting, is used in the treatment of severe chronic depression because it inhibits5-hydroxytryptamine (serotonin) and norepinephrine reuptake [11]. Beyond its actions on the central nervous system, imipramine also has other biological effects, such as immunosuppressive properties through the modulation of inflammatory cytokine production and the induction of autophagic death in tumor cells [12, 13]. The antileishmanial effects of imipramine and its analogs were first demonstrated in the 1980s in promastigotes and amastigotes of L. donovani and L. major [14]. Imipramine also exhibited activity against antimony-resistant intracellular amastigotes without affecting the host cells. Additionally, oral treatment with imipramine reduced the parasite burden of visceral leishmaniasis in hamsters [15].

Tricyclic antidepressants have high affinity for the phosphatidylcholine and phosphatidylethanolamine in lipid membranes, causing changes in lipid-protein interactions [16]. Another interesting feature of imipramine is its effect on methyltransferases. Imipramine has been described to inhibit the activity of catechol-O-methyltransferase (COMT), DNA methyltransferase and the methylation of phospholipids in the plasma membrane [17, 18].

The sterol biosynthesis pathway of trypanosomatids has diverged from that in mammalians such that these parasites produce ergosterol derivatives instead of cholesterol [19]. It is assumed that this biosynthetic pathway is essential in Leishmania because pharmacological inhibition of different steps results in the death of the parasite [2025]. Methylation by C-24methyltranferase is one of final steps of sterol biosynthesis in Leishmania, and this reaction does not occur in mammalians. Inhibition of this enzyme by azasterols causes the accumulation of cholestane derivatives and leads to parasite death [26].

Here we investigated the effects of imipramine on the sterol biosynthesis of L. amazonensis and its leishmanicidal activity in combination with miconazole, a well-known inhibitor of this pathway.

Methods

Drugs

Miconazole and imipramine were provided by Sigma–Aldrich (St. Louis, USA) and stored at -20o C in DMSO (Sigma-Aldrich) stock solution (10 mM).

Maintenance and cultivation of parasites

Promastigotes of Leishmania amazonensis (strain MHOM/BR/77/LTB0016) were maintained at 26 °C in RPMI medium (Sigma- Aldrich) supplemented with 10 % fetal bovine serum (FBS), 100 μg/ml streptomycin, 100 U/ml penicillin and 5 mg/ml hemine. Subcultures were performed twice a week until the tenth passage. Afterwards, old cultures were discarded and fresh parasites were obtained from infected BALB/c mice.

Antipromastigote activity

Promastigotes of L. amazonensis were maintained in cell culture flasks at 26 °C in RPMI medium without phenol red (Sigma- Aldrich) supplemented as described above. Experiments were performed on promastigotes in 96-well plates, with an initial inoculum of 1.0 × 106cells/ml and compound concentrations of up to 24 μM of miconazole and to 100 μM of imipramine. In the combination experiments, the concentrations were up to 24 μM of miconazole and 12.5 μM of imipramine. Plates were incubated at 26 °C for 72 hours. After this period, parasite growth was evaluated by adding 10 % tetrazolium salt (MTT, Sigma-Aldrich) (5 mg/ml) per well. The plates were incubated at 26 °C for a further hour, and formazan crystals were dissolved by adding 80 μl of DMSO to each well. The reaction was analyzed using a spectrophotometer at 570 nm wavelength. IC50 values were obtained by non-linear regression using the GraphPad Prism 6 software (GraphPad Software Inc., La Jolla, USA). The fractional inhibitory concentration (FIC) determined to analyze whether the combination treatments were synergistic was calculated as follows: FIC = IC50 of drug A in combination/IC50 of drug A alone + IC50 of drug B in combination/IC50 of drug B alone. The arithmetic mean of the FICs obtained for each concentration was interpreted according to published guidelines: synergy (FIC ≤ 0.5), antagonism (FIC ≥ 4.0) and additive effect (no interaction) (0.5 < FIC < 4.0) [27].

Antiamastigote activity

Peritoneal macrophages from BALB/c mice were infected with promastigotes of L. amazonensis in Lab-Tek chambers (Nunc, Roskilde, Denmark) and kept at 37 °C. After four hours, the chambers were washed, and the cultures were treated with miconazole alone or in combination with imipramine in supplemented RPMI medium for 72 hours. Various concentrations were used for these studies, with up to 16 μM of miconazole and 50 μM of imipramine. In the combination assays, the concentration of imipramine was fixed at 12.5 μM and the concentration of miconazole varied, with the maximum concentration being 16 μM. After incubation, the slides were stained, and the infection rate was determined by counting the infected macrophages under a light microscope. The infection rate was calculated using the formula: % infected macrophages × number of amastigotes/number of total macrophages.

Toxicity to macrophages

Mouse peritoneal macrophages in 96-well plates were treated with imipramine and miconazole alone or in combination for 72 hours at 37 °C. After this period, the cell viability was evaluated by adding 10 % tetrazolium salt (MTT) (5 mg/ml) to each well. The plates were incubated at 37 °C for another four hours, and the resulting formazan crystals were dissolved by adding 80 μl DMSO to each well. The plates were then read at 570 nm. The results were expressed as the percentage of viable cells compared to the untreated control.

Extraction of lipids

Lipids from promastigotes of L. amazonensis were extracted using the method reported by Bligh & Dyer [28]. Briefly, samples were pelleted, and a solution of methanol, chloroform and water (2:1:0.5 v/v) was added. After stirring the mixture for one hour, the samples were centrifuged for 20 min at 3,000 rpm and the supernatant containing the lipids was separated from the precipitate. The precipitate was subjected to a second extraction under the same conditions. The supernatants were combined, and methanol/chloroform/water (1:0.5:0.4 v/v) was added. After 40 seconds of stirring, the material was centrifuged (3,000 rpm/30 min) again. The lower layer (organic) containing the lipids was then separated with the aid of a glass syringe and was transferred to a 1.5 ml tube resistant to organic solvents (Axygen Scientific, Inc., Union City, CA, USA). The solvent was evaporated under an N2 flux, and the lipids were analyzed by gas chromatography- mass spectrometry (GC/MS), as described below.

Analysis of the sterol profile by gas chromatography coupled with mass spectrometry (GC/MS)

Promastigotes of L. amazonensis were cultured with 15 or 30 μM imipramine or 4 μM miconazole or in culture medium alone. After 72 hours, 1×108 parasites from each culture were washed three times in cold PBS (pH 7.5), and the sterols were extracted as described in Section 3.6. The samples were injected into a GC/MS - QP2010 Ultra Machine (Shimadzu Scientific Instruments, Tokyo, Japan). After injection, the column temperature was maintained at 50 °C for one minute and then increased to 270 °C at a rate of 10 °C/min and finally to 300 °C at a rate of 1 °C/min. The flow of the carrier gas (He) was kept constant at 1.1 ml/min. The temperatures of the injector and detector were 250 °C and 280 °C, respectively [29].

Ethical approval

Macrophages from BALB/c mice were obtained in accordance with protocols approved by the Ethics Committee for Animal Use of the Instituto Oswaldo Cruz (L026/2015).

Results and discussion

Imipramine has effects on the cell growth and membrane functions of L. donovani and L. major [14]. Antidepressants cause lethal disruption of their membrane function, reductions in mitochondrial proton motive force and apoptosis in Leishmania spp. [30]. In addition to the effects on the parasite itself, imipramine is also a potent inducer of TNF-α in macrophages, which is an important cytokine for antileishmanial defense [31]. Tricyclic antidepressants (imipramine, desipramine, amitriptyline and nortriptyline) are amphiphilic molecules that accumulate in membranes and alter their biophysical characteristics [16, 32]. Imipramine has also been demonstrated to inhibit the three main classes of methyltransferases (N, O and C-methyltransferases). The activity of phosphatidylethanolamine N-methyltransferase was also found to be inhibited by imipramine and chlorpromazine [33]. Moreover, imipramine has inhibitory effects on erythrocyte catechol-O-methyltransferase and indirectly inhibits DNA methylation by cytosine C-methyltransferase [17, 34].

Considering the affinity of imipramine for membranes and its effects on methyltransferases, we hypothesized that imipramine may interfere with the sterol metabolism of parasites. Therefore, we analyzed the sterol composition of promastigotes of L. amazonensis when they were exposed to imipramine. Table 1 shows the results of an analysis of the relative amount of each sterol. The promastigotes treated with imipramine showed a decrease in cholesterol (1) and in the ergostane-derived sterols (C24-methylated sterols) ergosta-5,7,24-trien-3β-ol (dehydroepisterol) (5) and ergosta-7,24-dien-3β-ol (episterol) (6). Interestingly, we also observed a concomitant accumulation of cholestane-derived sterols (C24-demethylated sterols), cholesta-5,7,22-trien-3β-ol (2), cholesta-7-24-dien- 3β-ol (3).
Table 1

Effects of imipramine and miconazole on the sterol composition of L. amazonensis promastigotes

  

C

Imipramine 15 μM

Imipramine 30 μM

Miconazole 4 µM

Substance

PM

Relative amount (%)

(1) Cholesterol (exogenous)

386

9.49

7,76

5,4

15.04

(2) Cholesta-5,7,22-trien-3β-ol

382

-

28,1

40,33

-

(3) Cholesta-7-24-dien- 3β-ol

384

-

2,45

4,11

-

(4) 14α-metilergosta-8,24 (241)-dieno-3β-ol

412

-

-

-

46.40

(5) Ergosta-5,7,24-trien-3β-ol (dehydroepisterol)

396

83,4

56,07

48,67

4.15

(6) Ergosta-7,24-dien-3β-ol (Episterol)

398

7,1

5,62

1,49

-

(7) 4α,14α-dimetilergosta-8,24 (241)-dieno-3β-ol

(Obtusofoliol)

426

-

-

-

34.41

C – Untreated control

Azasterols inhibit the C24 sterol methyltransferase, an enzyme required for the production of the typical ergostane- and stigmastane-based sterols, which are not found in mammalian cells [35]. Azasterols interfere with the sterol biosynthesis of T. cruzi and Leishmania spp., resulting in cell growth arrest and death [36]. The treatment of L. donovani promastigotes with azasterol altered their sterol profile, leading to a global decrease in 24-methylsterols and an increase in demethylated sterols [37]. This effect is similar to that observed following the treatment with imipramine (Table 2), suggesting that it occurs via a similar mechanism of action.
Table 2

Relative proportions of 24-methylated and 24-demethylated sterols from L. amazonensis promastigotes treated with imipramine

 

Imipramine

 

0

15 μM

30 μM

% 24-alkylated

90.51

61.69

50.16

% 24-nonalkylated

0

30.55

44.44

Various inhibitors of sterol biosynthesis (azoles, statins and allylamines) have been extensively studied in Leishmania spp., confirming that this pathway is an excellent target for the chemotherapy of leishmaniasis [19, 2125, 37, 38]. As seen in Table 1, treatment with miconazole disturbs the sterol synthesis in a different fashion than imipramine, causing the accumulation of C14 methyl sterols, 14α-metilergosta-8,24 (241)-dieno-3β-ol (4) and obtusofoliol (7), sterols that typically accumulate following the inhibition of C14 demethylase [20].

Using a combination of drugs that act on different points of the same pathway has been noted to represent an interesting strategy for antimicrobial chemotherapy [20, 21]. Haughan et al. demonstrated that the combination of lovastatin (an HMGCoA reductase inhibitor) and miconazole (C14-demethylase inhibitor) led to synergistic activity against promastigotes of L. amazonensis [23]. Therefore, since both drugs (imipramine and miconazole) interfere with the sterol synthesis pathway, but generate different aberrant metabolites, we decided to evaluate the effects of their combination on the parasite growth. The antileishmanial activity of imipramine alone and in combination with miconazole in the promastigotes of L. amazonensis is shown in Fig. 1a and b. The effects of the combination were expressed graphically as an isobologram, where the IC50values of the drugs alone and in combination were plotted. The fractional inhibitory concentration index (FICI) was calculated to classify the interaction as synergistic, antagonistic or additive. As expected, miconazole was active against promastigotes, with an IC50 of 4.7 ± 1.03 μM. Imipramine also proved to be active alone, with an IC50 of 28.63 ± 1.2 μM. The combination resulted in an additive effect, as observed in the isobologram, with a FICI value of 0.83 (Fig. 1b-c), suggesting that imipramine and miconazole can be used in combination, as no antagonistic effect was observed.
Fig. 1

Antipromastigote activity of imipramine, miconazole and their combination. Promastigotes of L. amazonensis were incubated with different concentrations of imipramine with or without miconazole for 72 hours at 26 °C. a imipramine, b imipramine + miconazole c an isobologram. Each plotted point in the isobologram is the IC50 of the drugs alone or in combination. The straight line connecting the individual IC50values represents the theoretical line of additivity. The experiments were performed in triplicate, n = 3. The graphs are representative of one experiment, and the standard deviations are shown. The graphics and IC50 values were obtained using the GraphPad Prism 4 software. * P < 0.05, ** P < 0.01, *** P <0.001

Before testing the effects on intracellular amastigotes, we evaluated the toxicity of imipramine alone and in combination with miconazole in host cells. Uninfected peritoneal macrophages showed no signs of toxicity when incubated with imipramine alone at concentrations less than 50 μM (Fig. 2a). Miconazole also showed no toxic effects, even when used in combination with imipramine (Fig. 2b-c).
Fig. 2

Effect on the toxicity of inhibitors peritoneal macrophages. Uninfected macrophages were incubated with imipramine, miconazole alone or the combination of the two agents for 72 hours at 37 °C. After this period, the cells were incubated with MTT for 1 hour at 37 °C, and the absorbance was read at 570 nm. a imipramine, b miconazole c 12.5 μM imipramine (IMP) + miconazole. The experiments were performed in triplicate, n = 3

In the next step, we assessed the activity of imipramine against intracellular amastigotes, the clinically significant stage of the parasite. The IC50 was found to be 13.32 ± 1.1 μM (Fig. 3a). Due to the experimental difficulty associated with performing a “checkerboard” approach to draw isobolograms for antiamastigote activity, we fixed the concentration of imipramine at 12.5 μM and varied the concentration of miconazole to calculate the IC50 and IC90 values of the combination. When used in combination with imipramine, the IC50 of miconazole was reduced from 2.2 ± 0.2 μM to 0.5 ± 0.1 μM and the IC90 was reduced from 3.9 ± 0.2 μM to 2.2 ± 0.1 μM (Fig. 3b).
Fig. 3

Antiamastigote activity of the combination of imipramine and miconazole. Peritoneal macrophages infected with L. amazonensis that were left untreated or treated with imipramine and miconazole were incubated for 72 hours at 37 °C. After incubation, the cells were fixed and stained. The infection rate was calculated using the formula: % infected MØ x number of amastigotes/total No. MØ. a imipramine b miconazole + 12.5 μM imipramine. The experiments were performed in triplicate, n = 3. The graphs are representative of one experiment, and the standard deviations are shown. * P < 0.05, ** P < 0.01, *** P < 0.001

In addition to having its own machinery for sterol biosynthesis, Leishmania also uptakes a significant amount of exogenous cholesterol, mainly through the endocytosis of LDL particles [39]. Andrade-Neto et al. have described that the inhibition of the sterol pathway in L. amazonensis increases the intake of cholesterol from the culture medium [40]. Interestingly, imipramine has been reported to block the release of cholesterol from lysosomes in mammalian cells, especially from the endocytosis of LDL particles, preventing its distribution for use by the cell [41, 42]. Therefore, it is possible that imipramine is interfering with both the biosynthesis and utilization of exogenous sources of sterols, so further studies are needed to address this issue.

Conclusion

In summary, we have demonstrated that imipramine has antileishmanial activity, most likely by affecting the sterol biosynthesis of the parasites. The combination of imipramine with miconazole can improve the antileishmanial activity. These findings suggest that imipramine could be useful to treat leishmaniasis, particularly if used in combination with other inhibitors of sterol biosynthesis.

Declarations

Acknowledgments

TMP and ECTS are CNPq fellows. VVAN is a CAPES fellow. ECTS received a grant from the Programa Estratégico de Apoio à Pesquisa em Saúde, FIOCRUZ (PAPES/CNPq; grant 407680/2012-8).

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Laboratório de Bioquímica de Tripanosomatídeos, Instituto Oswaldo Cruz, FIOCRUZ

References

  1. Jhingran A, Chatterjee M, Madhubala R. Leishmaniasis: epidemiological trends and diagnosis. In: Myler PJ, Fasel N, editors. Leishmania - After the genome. USA: Caister Academic Press; 2008. p. 1–14.Google Scholar
  2. Marra F, Chiappetta MC, Vincenti V. Ear, nose and throat manifestations of mucocutaneous Leishmaniasis: a literature review. Acta Biomed. 2014;85(1):3–7.PubMedGoogle Scholar
  3. Neuber H. Leishmaniasis. J Dtsch Dermatol Ges. 2008;6:754–64.View ArticlePubMedGoogle Scholar
  4. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M; WHO Leishmaniasis Control Team. WHO Leishmaniasis Control Team: Leishmaniasis Worldwide and Global Estimates of Its Incidence. Plos One. 2012;7(5):e3567.Google Scholar
  5. Sundar S, Chakravarty J. Leishmaniasis: an update of current pharmacotherapy. Expert Opinion on Pharmacother. 2013;14:53–63.View ArticleGoogle Scholar
  6. Oliveira LF, Schubach AO, Martins MM, Passos SL, Oliveira RV, Marzochi MC, Andrade CA. Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta Trop. 2011;118:87–96.Google Scholar
  7. Singh N, Chatterjee M, Sundar S. The overexpression of genes of thiol metabolism contribute to drug resistance in clinical isolates of visceral leishmaniasis (kala azar) in India. Parasit Vectors. 2014;17:7–596.Google Scholar
  8. Kesselheim AS, Maggs LR, Sarpatwari A. Experience with the priority review voucher program for drug development. JAMA. 2015;314:1687–8.View ArticlePubMedGoogle Scholar
  9. Rijal S, Ostyn B, Uranw S, Rai K, Bhattarai NR, Dorlo TP, Beijnen JH, Vanaerschot M, Decuypere S, Dhakal SS, Das ML, Karki P, Singh R, Boelaert M, Dujardin JC. Increasing failure of Miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. Clin Infect Dis. 2013;56:1530–8.Google Scholar
  10. de Matos Guedes HL, da Silva Costa BL, Chaves SP, de Oliveira Gomes DC, Nosanchuk JD, De Simone SG, Rossi-Bergmann B. Intranasal vaccination with extracellular serine proteases of Leishmania amazonensis confers protective immunity to BALB/c mice against infection. Parasit Vectors. 2014;7:448.Google Scholar
  11. Obonaga R, Fernández OL, Valderrama L, Rubiano LC, Castro Mdel M, Barrera MC, Gomez MA, Gore Saravia N. Treatment failure and Miltefosine susceptibility in dermal leishmaniasis caused by Leishmania subgenus Viannia species. Antimicrob Agents Chemother. 2014;58(1):144–52.Google Scholar
  12. Racagni G, Popoli M. The pharmacological properties of antidepressants. Int Clin Psychopharmacol. 2010;25(3):117–31.View ArticlePubMedGoogle Scholar
  13. Kenis G, Maes M. Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacol. 2002;5(4):401–12.View ArticlePubMedGoogle Scholar
  14. Jeon SH, Kim SH, Kim Y, Kim YS, Lim Y, Lee YH, Shin SY. The tricyclic antidepressant imipramine induces autophagic cell death in U-87 MG glioma cells. Biochem Biophys Res Commun. 2011;413(2):311–7.Google Scholar
  15. Zilberstein D, Dwyer DM. Antidepressants cause lethal disruption of membrane function in the human protozoan parasite Leishmania. Science. 1984;226(4677):977–9.View ArticlePubMedGoogle Scholar
  16. Mukherjee S, Mukherjee B, Mukhopadhyay R, Naskar K, Sundar S, Dujardin JC, Das AK, Roy S. Imipramine is an orally active drug against both antimony sensitive and resistant Leishmania donovani clinical isolates in experimental infection. PLoS Negl Trop Dis. 2012;6(12):e1987.Google Scholar
  17. Fisar Z. Interactions between tricyclic antidepressants and phospholipid bilayer membranes. Gen Physiol Biophys. 2005;24(2):161–80.PubMedGoogle Scholar
  18. Zimmermann N, Zschocke J, Perisic T, Yu S, Holsboer F, Rein T. Antidepressants inhibit DNA methyltransferase 1 through reducing G9a levels. Biochem J. 2012;448(1):93–102.View ArticlePubMedGoogle Scholar
  19. Ahyayauch H, Bennouna M. Interaction of chlorpromazine and imipramine with model membranes. Therapie. 1999;54(5):585–8.PubMedGoogle Scholar
  20. Roberts CW, McLeod R, Rice DW, Ginger M, Chance ML, Goad LJ. Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. Mol Biochem Parasitol. 2003;126:129–42.View ArticlePubMedGoogle Scholar
  21. Rodrigues JC, Attias M, Rodriguez C, Urbina JA, Souza W. Ultrastructural and biochemical alterations induced by 22,26-azasterol, a delta(24(25))-sterol methyltransferase inhibitor, on promastigote and amastigote forms of Leishmania amazonensis. Antimicrob Agents Chemother. 2002;46(2):487–99.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Vannier-santos MA, Urbina JA, Martiny A, Neves A, de Souza W. Alterations induced by the antifungal compounds Ketoconazole and Terbinafine in Leishmania. J of Eukaryot Microbiol. 1995;42:337–46.View ArticleGoogle Scholar
  23. Haughan PA, Chance ML, Goad LJ. Synergism In vitro of Lovastatin and Miconazole as antileishmanial agents. Biochem Pharmacol. 1992;44:2199–206.View ArticlePubMedGoogle Scholar
  24. Berman JD, Holz GG, Beach DH. Effects of Ketoconazole on growth and sterol biosynthesis of Leishmania mexicana promastigotes in culture. Mol Biochem Parasitol. 1984;12:1–13.View ArticlePubMedGoogle Scholar
  25. Macedo-Silva ST, Urbina JA, de Souza W, Rodrigues JC. In Vitro activity of the antifungal azoles Itraconazole and Posaconazole against Leishmania amazonensis. PLoS One. 2013;8(12):e83247.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Lorente SO, Rodrigues JC, Jiménez Jiménez C, Joyce-Menekse M, Rodrigues C, Croft SL, Yardley V, de Luca-Fradley K, Ruiz-Pérez LM, Urbina J, de Souza W, González Pacanowska D, Gilbert, LH. Novel azasterols as potential agents for treatment of leishmaniasis and trypanosomiasis. Antimicrob Agents Chemother. 2004;48(8):2937–50.Google Scholar
  27. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Anticrob Chemother. 2003;52(1):1.View ArticleGoogle Scholar
  28. Bligh EG, Dryer MJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37(8):911–3.View ArticlePubMedGoogle Scholar
  29. Torres-Santos EC, Sampaio-Santos MI, Buckner FS, Yokoyama K, Gelb M, Urbina JA, Rossi-Bergmann B. Altered sterol profile induced in Leishmania amazonensis by a natural dihydroxymethoxylated chalcone. J Antimicrob Chemother. 2009;63:469–72.Google Scholar
  30. Zilberstein D, Liveanu V, Gepstein A. Tricyclic drugs reduce proton motive force in Leishmania donovani promastigotes. Biochem Pharmacol. 1990;39(5):935–40.View ArticlePubMedGoogle Scholar
  31. Kubera M, Kenis G, Bosmans E, Kajta M, Basta-Kaim A, Scharpe S, Budziszewska B, Maes M. Stimulatory effect of antidepressants on the production of IL-6. Int Immunopharmacol. 2004;4(2):185–92.Google Scholar
  32. Giraud F, Claret M, Bruckdorfer KR, Chailley B. The effects of membrane lipid order and cholesterol on the internal and external cationic sites of the Na + -K+ pump in erythrocytes. Biochim Biophys Acta. 1981;647(2):249–58.View ArticlePubMedGoogle Scholar
  33. Melzacka M, Janczar L, Nocon H. The effects of imipramine on the methylation of phosphatidylethanolamine (PE) in the cortical membranes of Wistar rats. Biochem Pharmacol. 1993;46(3):449–53.View ArticlePubMedGoogle Scholar
  34. Hoo JJ, Noldt P, Beckermann WJ, Agarwal DP, Goedde HW. In vitro effect of haloperidol, chlorpromazine, imipramine and lithium on the erythrocyte catechol-O-methyltransferase. Arzneimittelforschung. 1982;32(6):681–3.PubMedGoogle Scholar
  35. Haughan PA, Chance ML, Goad LJ. Effects of an azasterol inhibitor of sterol 24-transmethylation on sterol biosynthesis and growth of Leishmania donovani promastigotes. Biochem J. 1995;308:31–8.View ArticlePubMedPubMed CentralGoogle Scholar
  36. Gigante F, Kaiser M, Brun R, Gilbert IH. SAR studies on azasterols as potential anti-trypanosomal and anti-leishmanial agents. Bioorg Med Chem. 2009;17(16):5950–61.View ArticlePubMedGoogle Scholar
  37. Magaraci F, Jimenez CJ, Rodrigues C, Rodrigues JC, Braga MV, Yardley V, de Luca-Fradley K, Croft SL, de Souza W, Ruiz-Perez LM, Urbina J, Gonzalez Pacanowska D, Gilbert IH. Azasterols as inhibitors of sterol 24-methyltransferase in Leishmania species and Trypanosoma cruzi. J Med Chem. 2003;46(22):4714–27.Google Scholar
  38. Medina JM, Rodrigues JCF, De Souza W, Atella GC, Barrabin H. Tomatidine promotes the inhibition of 24-alkylated sterol biosynthesis and mitochondrial dysfunction in Leishmania amazonensis promastigotes. Parasitology. 2012;139:1253–65.View ArticlePubMedGoogle Scholar
  39. Bastin P, Stephan A, Raper J, Saint-Remy JM, Opperdoes FR, Courtoy PJ. An M(r) 145,000 low-density lipoprotein (LDL)-binding protein is conserved throughout the Kinetoplastida order. Mol Biochem Parasitol. 1996;76:43–56.View ArticlePubMedGoogle Scholar
  40. Andrade-Neto VV, Cicco NN, Cunha-Junior EF, Canto-Cavalheiro MM, Atella GC, Torres-Santos EC. The pharmacological inhibition of sterol biosynthesis in Leishmania is counteracted by enhancement of LDL endocytosis. Acta Trop. 2011;119:194–8.View ArticlePubMedGoogle Scholar
  41. Howe D, Heinzen RA. Coxiella burnetii inhabits a cholesterol-rich vacuole and influences cellular cholesterol metabolism. Cell Microbiol. 2006;8(3):496–507.View ArticlePubMedGoogle Scholar
  42. Underwood KW, Andemariam B, McWilliams GL, Liscum L. Quantitative analysis of hydrophobic amine inhibition of intracellular cholesterol transport. J Lipid Res. 1996;37(7):1556–68.PubMedGoogle Scholar

Copyright

© Andrade-Neto et al. 2016

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.